Alliance Global raised the firm’s price target on Quoin Pharmaceuticals (QNRX) to $35 from $25 and keeps a Buy rating on the shares. The firm, which notes that its price target is based on a sum-of-the-parts analysis, says its higher target is primarily based on the higher value being placed on priority review vouchers.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNRX:
- Quoin Pharmaceuticals Ltd – ADR trading resumes
- Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause
- Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA
- Quoin Wins FDA Fast Track for QRX003 in Netherton
- Quoin Pharmaceuticals receives U.S. Fast Track Designation to QRX003